Apollo Hospitals Enterprise, India’s largest listed hospital chain, reported a strong September quarter on Wednesday, with consolidated net profit rising 32 per cent to Rs 630 crore. The growth came from steady demand for complex treatments, higher bed occupancy and a sharp rise in revenue from its core healthcare services business. But the market reaction told a different story. Shares of the Chennai-based company slipped on Thursday as investors weighed the cost of its aggressive expansion against the headline numbers.
The results, announced on November 4, were broadly in line with what analysts had pencilled in. Brokerages tracked by LSEG had expected a profit of around Rs 636 crore, so the actual figure of Rs 630 crore landed just a shade below estimates. Revenue from operations grew 23 per cent from a year earlier to Rs 7,615 crore, helped by a 23 per cent jump in the healthcare services segment and growth in the offline pharmacy business.
Complex care drives the quarter
The quarter’s standout was the hospital business itself. More patients walked in for complex procedures, the kind of specialised treatments that bring in higher revenue per bed. Bed occupancy improved to 73 per cent, up from 69 per cent a year ago, a sign that Apollo’s hospitals were fuller and busier through the quarter.
Established hospitals, the ones that have been running for years, held a healthy operating margin of 25.8 per cent. That is the engine of the business, and it kept running well. The pressure came from the other end: new hospitals. Losses and pre-operating expenses at newer facilities came to Rs 34.8 crore, a reminder that opening hospitals costs money long before the beds fill up.
Overall, the operating margin at the hospitals business narrowed by about 60 basis points to 24 per cent. It is a small slip, but in a quarter where profit rose by nearly a third, it was enough to make analysts pause.
Why the shares fell
Apollo’s shares fell 3.4 per cent to Rs 8,310.10 in early trade on Thursday, even as the broader Nifty 50 rose 1.68 per cent. The fall was not about the profit number. It was about what comes next.
Brokerages flagged two worries. First, the expansion programme itself: Apollo is adding hospitals at a fast pace, and each new facility drags on near-term profitability until it reaches scale. Second, the regulatory backdrop, including a possible cap on trade margins for oncology drugs and a regulatory notice on hospital margins.
Citi, which tracks the stock closely, noted that new hospitals posted losses while established ones stayed strong. The message from the Street was clear: the core business is healthy, but the growth bill is getting bigger.
What the numbers say
- Net profit: Rs 630 crore, up 32 per cent from Rs 477 crore a year ago
- Revenue: Rs 7,615 crore, up 23 per cent year on year
- Healthcare services revenue: up 23 per cent
- Bed occupancy: 73 per cent, up from 69 per cent
- Established hospital margin: 25.8 per cent
- New hospital losses and pre-operating costs: Rs 34.8 crore
- Share reaction: down 3.4 per cent to Rs 8,310.10 on Thursday
A familiar pattern for hospital stocks
Apollo’s quarter fits a pattern that investors in Indian hospital stocks know well. Demand for quality healthcare keeps rising, especially for complex and specialised care, and the big chains are expanding to meet it. The expansion brings revenue growth, but it also brings costs that show up before the returns do.
The question for the next few quarters is whether the new hospitals start contributing faster than they cost. If occupancy keeps climbing and the new facilities stabilise, the margin pressure should ease. If the regulatory overhang on drug margins grows, the Street may stay cautious.
What to watch next
Investors will watch three things in the coming months. First, how quickly the new hospitals move toward profitability. Second, whether occupancy holds above 73 per cent as more beds come online. And third, any clarity from regulators on the oncology drug margin issue, which analysts have flagged as a key risk to hospital earnings across the sector.
FAQs
How much profit did Apollo Hospitals make in Q2 FY27?
Apollo Hospitals reported a consolidated net profit of Rs 630 crore for the quarter ended September 30, 2026, up 32 per cent from Rs 477 crore a year earlier.
What was Apollo Hospitals’ revenue in the September quarter?
Revenue from operations rose 23 per cent year on year to Rs 7,615 crore, led by a 23 per cent jump in the healthcare services business.
Why did Apollo Hospitals shares fall after the results?
Shares fell 3.4 per cent to Rs 8,310.10 on Thursday as analysts flagged margin pressure from expansion costs at new hospitals and regulatory worries, including a possible cap on oncology drug trade margins.
What was Apollo Hospitals’ bed occupancy in Q2?
Bed occupancy improved to 73 per cent, up from 69 per cent a year ago, driven by strong demand for complex procedures.
When did Apollo Hospitals announce its Q2 results?
The company announced its September quarter results on Wednesday, November 4, 2026.
Apollo’s September quarter shows a hospital business in strong demand, with profits up by nearly a third. The market’s cool reaction is less about the quarter gone by and more about the cost of the growth still to come.
